ENTITY – Page 336

CSL Vifor Proposes Corrective Campaign to Resolve EU Antitrust Probe

2 years ago talkbio0Tagged Antitrust Probe, competition, Corrective Campaign, CSHL1 gene, EU, Multi-Channel Communication, Vifor

CSL Vifor, EU Antitrust Probe, Corrective Campaign, Multi-Channel Communication, Competition

Roche’s Alecensa Gains FDA Approval for Postsurgical Early Lung Cancer Treatment

2 years ago talkbio0Tagged Alecensa, Approved, Malignant neoplasm of lung, Postsurgical, Roche (company), United States Food and Drug Administration

Roche, Alecensa, FDA approval, Postsurgical treatment, Early lung cancer

Sanofi Restructures US Commercial Vaccine Group Amid Cost-Saving Campaign

2 years ago talkbio0Tagged Commercial Vaccine, Cost-Savings Campaign, Effectiveness, Efficiency, Employee, Evolving, Market, Optimization, Outplacement, restructuring, sanofi, streamlined strategic sales, Structure, Vaccines

Sanofi, Restructuring, US Commercial Vaccine Group, Cost-Savings Campaign, Streamlined Strategic Sales Structure, Evolving Vaccine Market, Optimization for Efficiency and Effectiveness, Employee Support and Outplacement Assistance

Vertex’s Acquisition of Alpine Immune Sciences for Povetacicept: Humira-like Potential in IgAN, but Indication Variations Matter

2 years ago talkbio0Tagged ALPN-303, Humira-like potential, IGA Glomerulonephritis, multiple autoimmune diseases, Povetacicept

Vertex, Alpine Immune Sciences, Povetacicept (ALPN-303), IgA nephropathy (IgAN), Humira-like potential, Multiple autoimmune diseases

Biopharma Layoff Tracker 2024: Sanofi, Vedanta, Fujifilm, and More Companies Reduce Workforce

2 years ago talkbio0Tagged Acorda, Biological Factors, Biopharma layoffs, Cara, Eiger, Fujifilm, Genomic Orientation, Invitae, Pfizer, sanofi, Vedanta

Biopharma layoffs, Sanofi, Vedanta, Fujifilm, Acorda Therapeutics, Eiger BioPharmaceuticals, Invitae, Sientra, Strand Therapeutics, Cara Therapeutics, Pfizer

Alecensa: FDA-Approved First ALK Inhibitor for Adjuvant Treatment in Early-Stage ALK-Positive NSCLC

2 years ago talkbio0Tagged Alecensa, ALINA, ALK gene, ALK Positive, Approved, Cessation of life, disease recurrence, Early-stage, genentech, Guidelines, Immunologic Adjuvants, Inhibitor, NCCN, Non-Small Cell Lung Carcinoma, Roche (company), United States Food and Drug Administration

Alecensa, ALK Inhibitor, Adjuvant Treatment, Early-Stage ALK-Positive NSCLC, FDA Approval, Genentech, Roche Group, ALINA Study, 76% Reduction in Disease Recurrence or Death, NCCN Guidelines